医学
HBeAg
乙型肝炎表面抗原
内科学
血清转化
乙型肝炎病毒
乙型肝炎
荟萃分析
随机对照试验
相对风险
免疫学
置信区间
病毒
作者
Feng-li Zheng,Zhijun Tan,Wenzhi Xiang,Liang Zhou
出处
期刊:Pediatric Infectious Disease Journal
[Ovid Technologies (Wolters Kluwer)]
日期:2023-07-31
卷期号:42 (11): 942-948
被引量:1
标识
DOI:10.1097/inf.0000000000004057
摘要
Background: Chronic hepatitis B virus (HBV) infection burden in children remains a pressing public health concern. Whether antiviral therapy should be administered to children with HBV in the immune-tolerant phase remains controversial. We performed a meta-analysis to evaluate antiviral therapy efficacy and safety in children with immune-tolerant hepatitis B (ITHB). Methods: A search was conducted in multiple databases (PubMed, Embase, Cochrane, Web of Science, CBM, CNKI and Wanfang Data) to identify clinical trials examining antiviral therapy efficacy and safety in children (1–18 years) with ITHB viral infection from inception to February 2023. Outcomes were calculated separately for controlled and single-arm studies. Results: Nine trials (442 patients), including 2 randomized controlled trials (RCTs), 3 non-RCTs and 4 single-arm studies, were included in this meta-analysis. In the RCTs, antiviral therapy group exhibited greater rates of HBsAg loss [risk ratio (RR) = 6.11, 95% confidence interval (CI): 1.67–22.31, P Z-test = 0.006], HBsAg serologic response (RR = 5.29, 95% CI: 1.47–19.07, P Z-test = 0.011) and HBeAg loss (RR = 3.00, 95% CI: 1.35–6.66, P Z-test = 0.007) compared with the control group at the end of follow-up. In single-arm studies, the pooled incidences of HBsAg loss, HBeAg loss and HBsAg seroconversion were 24% (95% CI: −0.1% to 48%), 24% (95% CI: −0.1% to 48%) and 24% (95% CI: −5% to 52%), respectively. Conclusion: Current evidence suggests the effectiveness of antiviral therapy in children with HBV infection in the immune-tolerant stage, with few serious adverse events. Due to the limited quality and number of included studies, more high-quality studies are required to validate our findings.
科研通智能强力驱动
Strongly Powered by AbleSci AI